Luke Evnin, a director at Werewolf Therapeutics, Inc. (NASDAQ: HOWL), sold 30,616 shares of the company’s stock on January 14, 2024. The shares were traded at an average price of $0.57, resulting in a total transaction value of $17,451.12. Following this sale, Evnin retains ownership of 2,236,055 shares, which are currently valued at approximately $1,274,551.35. This transaction reflects a decrease of 1.35% in his ownership stake.
The details of this sale were disclosed through a legal filing with the U.S. Securities and Exchange Commission (SEC). Such disclosures are essential for transparency in corporate governance, especially in publicly traded companies.
Current Stock Performance and Financial Metrics
As of the most recent trading session on January 14, shares of Werewolf Therapeutics opened at $0.55. The company is currently showing a quick ratio of 3.87 and a current ratio of 3.87, indicating a strong liquidity position. Its debt-to-equity ratio stands at 0.73. Over the past fifty days, the stock has averaged $0.84, while its two-hundred day moving average is $1.23.
The stock has experienced a volatile year, with a 52-week low of $0.53 and a high of $2.38. Presently, the company has a market capitalization of $26.74 million, a price-to-earnings ratio of -0.34, and a beta value of 0.77, suggesting that it is less volatile than the broader market.
Institutional Investment Activity
Recent activity among institutional investors highlights their interest in Werewolf Therapeutics. Several hedge funds have either increased or initiated positions in the company. Notably, Quadrature Capital Ltd acquired a new stake valued at approximately $28,000 during the second quarter, while Qube Research & Technologies Ltd added shares worth about $48,000.
Additionally, AQR Capital Management LLC invested around $79,000 in the first quarter, and Y Intercept Hong Kong Ltd purchased shares valued at around $92,000. Bridgeway Capital Management LLC notably increased its holdings by 157.7%, now owning 102,000 shares worth approximately $111,000. Overall, institutional investors and hedge funds control 64.84% of the company’s stock.
Analysts’ Perspectives and Ratings
Analysts have recently adjusted their ratings and price targets for Werewolf Therapeutics. According to a report by Citigroup, the stock rating was downgraded from “market outperform” to “market perform” on December 19, 2023. Bank of America also revised its target price from $8.00 to $7.00, maintaining a “buy” rating as of November 18, 2023.
In further assessments, HC Wainwright lowered its price objective from $10.00 to $4.00, while Wedbush adjusted its rating from “outperform” to “neutral,” setting a target price of $1.00. Overall, three analysts have given the stock a “Buy” rating, four have issued a “Hold” rating, and one has assigned a “Sell” rating. The consensus rating stands at “Hold,” with an average target price of $3.75, according to data from MarketBeat.
About Werewolf Therapeutics
Werewolf Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies aimed at treating solid tumors. The company utilizes its proprietary Conditional Activation Platform to keep therapeutic molecules inert in healthy tissues while selectively activating them in the tumor microenvironment. This approach aims to enhance anti-tumor efficacy and minimize systemic toxicity. Currently, Werewolf is advancing multiple programs, including conditionally activated cytokine candidates and bi-specific antibody constructs.
As the company continues to develop its innovative therapies, the performance of its stock will likely remain under scrutiny from both analysts and investors.
